News Image

Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

Provided By Globe Newswire

Last update: Mar 25, 2022

DURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.

Read more at globenewswire.com
Follow ChartMill for more